Clinical Trial Search

Primary: Total Cholesterol (TC) Levels at First Acute Coronary Event — 163.5 mg/dL

Primary: Percentage of Triglyceride (TG) Change — -38.12 percentage of TG change

Primary: Changes Serum Triglyceride Levels — 223.1; 241.2; 227.0; 267.2 mg/dl — p=0.0001

Primary: Percent Change From Baseline for Apolipoprotein B (ApoB) at Day 180 — -11.6; -14.1; -24.3; -19.0 Percent change — p=0.691

Primary: Increase in Acid Sphingomyelinase (ASM) Expression and Activity in Bone Marrow-derived Endothelial Progenitor Cells (EPCs) — 0.2; 0.5 nM/hr

Primary: Gingival Crevicular Fluid Level of Malondialdehyde (MDA) as a Marker of Lipid Oxidation. — 144.09; 298.52; 802.09; 139.50 pg/ml

Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio

Primary: Mean ApoB Concentration Before and After Evolocumab — 75.9; 35.3 mg/dL — p=<0.001

Primary: Percent Change in Low-Density Lipoprotein Cholesterol (LDL-C) Level From Baseline to Week 12 — -31.19; -33.83; -41.09; -46.62 Percent Change (%) — p=< 0.001

Primary: Total Cholesterol Before and After Simvastatin/Ezetimibe Administration — 255; 253; 180; 215 mg/dl — p=<0.05

Primary: Triglycerides — 199; 216.9; 155.1; 177.6 mg/dL

Primary: Percent Changes From Baseline to End-of-treatment in Non-HDL Cholesterol, HDL Cholesterol, and Triglycerides by LCP-AtorFen Versus Atorvastatin Monotherapy — -44.8…

Primary: Percent Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) (mg/dL) — -0.3; -1.5 Percent Change — p=0.926

Primary: Number of Participants With One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration Part A and Part B — 0…

Primary: Percentage of Participants Achieving Target Lipid Values — 46.8 Percentage of participants

Primary: Basal HDL-cholesterol Level — 39.5 mg/dL

Primary: Triglycerides After 90 Days — 2.3; 1.1; 1.3 mmol/L

Primary: Change From Baseline to Week 4 in Plasma Lipoprotein-associated Phospholipase A2 (Lp-PLA2) Activity — 0.961; 0.494; 0.404; 0.313 Log(millimole per milliliter per minute)…

Primary: Mean Low Density Lipid-Cholesterol (LDL-C) Levels in High and Very High Risk Cardiovascular Participants — 2.40; 1.99 mmol/L

Primary: Rate of Cardiovascular (CV) Events — 7.91; 10.79; 12.77; 13.4 Events per 1000 patient-years

Primary: The GSK256073 Area Under Concentration-time Curve (AUC) and High Density Lipoprotein Cholesterol (HDLc) Data to Evolve the Exposure-response…

Primary: Percent Change From Baseline in Low Density Lipoprotein Cholesterol at Week 12 — -10.0; -5.5 Percent — p=0.006

Primary: Percent Change From Baseline in Non-HDL-C at Week 24: Overall Intent-to-treat (ITT) Analysis — -37.3; -4.7 Percent change — p=<0.0001

Primary: Percentage Change From Baseline in Low-density Lipoprotein Cholesterol (LDL-C) — -44.6; -46.9; -48.9; -50.4 Percentage Change

Primary: Change in Intestinal mRNA Expression Levels of LDL Receptor Between the Two 12-week Interventions — 110531; 95140 #copies/100000 copies housekeeping gene

Primary: Percent Change From Baseline to 12 Weeks Endpoint in High Density Lipoprotein Cholesterol (HDL-C) With LY2484595 in Combination With Atorvastatin and Atorvastatin…

Primary: Percent Change From Baseline in LDL-C at the Mean of Weeks 10 and 12 — 4.94; 0.99; -65.35; -69.05 percent change — p=<0.0001

Primary: Percentage of Participants Achieving LDL Level Less Than or Equal to (≤) 100 mg/dL at the 6 Month Visit — 51.52 percentage of participants

Primary: LDL Level Change From Baseline — -63.4; -54.6 mg/dl — p=0.391

Primary: Percent Change From Baseline Low Density Lipoprotein Cholesterol (LDL-C) — -40.78; -43.25 percent change